Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
12.420
Open
12.410
VWAP
12.16
Vol
103.32K
Mkt Cap
354.44M
Low
11.950
Amount
1.26M
EV/EBITDA(TTM)
--
Total Shares
27.42M
EV
323.68M
EV/OCF(TTM)
--
P/S(TTM)
10.18
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
10.60M
+36.4%
--
--
9.80M
+20.66%
--
--
9.20M
+17.08%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for ClearPoint Neuro, Inc. (CLPT) for FY2025, with the revenue forecasts being adjusted by 1.36% over the past three months. During the same period, the stock price has changed by -16.53%.
Revenue Estimates for FY2025
Revise Upward
+1.36%
In Past 3 Month
Stock Price
Go Down
-16.53%
In Past 3 Month
3 Analyst Rating
128.30% Upside
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 27.67 USD with a low forecast of 25.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
128.30% Upside
Current: 12.120
Low
25.00
Averages
27.67
High
30.00
128.30% Upside
Current: 12.120
Low
25.00
Averages
27.67
High
30.00
Stifel
Mathew Blackman
Strong Buy
Maintains
$19 → $25
2025-04-01
Reason
Stifel
Mathew Blackman
Price Target
$19 → $25
2025-04-01
Maintains
Strong Buy
Reason
B. Riley Securities
Neil Chatterji
Strong Buy
Maintains
$15 → $20
2025-01-28
Reason
B. Riley Securities
Neil Chatterji
Price Target
$15 → $20
2025-01-28
Maintains
Strong Buy
Reason
Lake Street
Frank Takkinen
Strong Buy
Maintains
$17 → $30
2025-01-21
Reason
Lake Street
Frank Takkinen
Price Target
$17 → $30
2025-01-21
Maintains
Strong Buy
Reason
Lake Street analyst Frank Takkinen raised the firm's price target on ClearPoint Neuro to $30 from $17 and keeps a Buy rating on the shares. While shares have had a meaningful move, the firm still does not think investors "fully appreciate" the potential of the partner business, says the analyst, who expects a basket of approved combo-therapies to be on the market over time and sees this providing "multiple growth opportunities" for ClearPoint.
Lake Street
Frank Takkinen
Strong Buy
Maintains
$11 → $15
2024-08-27
Reason
Lake Street
Frank Takkinen
Price Target
$11 → $15
2024-08-27
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Clearpoint Neuro Inc (CLPT.O) is -18.31, compared to its 5-year average forward P/E of -16.91. For a more detailed relative valuation and DCF analysis to assess Clearpoint Neuro Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-16.91
Current PE
-18.31
Overvalued PE
-7.63
Undervalued PE
-26.19
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-21.71
Current EV/EBITDA
-36.85
Overvalued EV/EBITDA
-9.71
Undervalued EV/EBITDA
-33.71
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
11.05
Current PS
8.54
Overvalued PS
17.26
Undervalued PS
4.83
Financials
Annual
Quarterly
FY2025Q1
YoY :
+11.07%
8.49M
Total Revenue
FY2025Q1
YoY :
+46.18%
-6.16M
Operating Profit
FY2025Q1
YoY :
+45.34%
-6.03M
Net Income after Tax
FY2025Q1
YoY :
+37.50%
-0.22
EPS - Diluted
FY2025Q1
YoY :
+65.49%
-6.36M
Free Cash Flow
FY2025Q1
YoY :
+2.09%
60.48
Gross Profit Margin - %
FY2025Q1
YoY :
-25.52%
-36.42
FCF Margin - %
FY2025Q1
YoY :
+30.86%
-71.02
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CLPT News & Events
Events Timeline
2025-05-13 (ET)
2025-05-13
16:46:31
ClearPoint Neuro reports Q1 revenue $8.5M, consensus $8.2M
2025-04-28 (ET)
2025-04-28
08:27:54
ClearPoint Neuro announces FDA submission to expand ClearPoint Prism labeling
2025-04-24 (ET)
2025-04-24
08:54:29
ClearPoint Neuro announces market release of Navigation Software Version 3.0
Sign Up For More Events
Sign Up For More Events
News
7.0
05-13SeekingAlphaClearPoint Neuro targets 15–20 new site activations in 2025 while advancing cell and gene therapy initiatives
9.5
05-13BenzingaClearPoint Neuro Reports Q1 Earnings: Revenue Beat, EPS Miss, Company Affirms FY25 Guidance
9.5
05-13NASDAQ.COMCLEARPOINT NEURO Earnings Results: $CLPT Reports Quarterly Earnings
Sign Up For More News
People Also Watch
KALV
Kalvista Pharmaceuticals Inc
11.430
USD
+1.87%
OBE
Obsidian Energy Ltd
4.915
USD
-0.71%
OFLX
Omega Flex Inc
32.650
USD
-2.42%
SPMC
Sound Point Meridian Capital Inc
18.100
USD
-0.22%
PSNL
Personalis Inc
4.795
USD
+2.24%
OTLY
Oatly Group AB (publ)
11.010
USD
-0.45%
HYLN
Hyliion Holdings Corp
1.670
USD
+46.49%
PKST
Peakstone Realty Trust
12.290
USD
-0.49%
DGICA
Donegal Group Inc
20.070
USD
-1.08%
KMDA
Kamada Ltd
6.880
USD
-1.01%
FAQ
What is Clearpoint Neuro Inc (CLPT) stock price today?
The current price of CLPT is 12.12 USD — it has decreased -3.35 % in the last trading day.
What is Clearpoint Neuro Inc (CLPT)'s business?
What is the price predicton of CLPT Stock?
What is Clearpoint Neuro Inc (CLPT)'s revenue for the last quarter?
What is Clearpoint Neuro Inc (CLPT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Clearpoint Neuro Inc (CLPT)'s fundamentals?
How many employees does Clearpoint Neuro Inc (CLPT). have?